The biotechnology company has entered negotiations with a major global pharmaceutical company, for the development and commercialisation of its lead drug candidate NBTXR3, after an extensive negotiation period and signed a non-binding term sheet
Nanobiotix has entered negotiations with a major global pharmaceutical company, over a final contract agreement for the development and commercialisation of its lead drug candidate NBTXR3.
The biotechnology company has entered the final contract negotiations, after an extensive negotiation period and signing a non-binding term sheet.
The arrangement is subject to negotiation and execution of a definitive agreement and each party’s requisite internal corporate approvals with respect to the definitive terms.
Nanobiotix is a France-based clinical biotechnology company engaged in developing disruptive, physics-based therapeutic approaches to enhance treatment outcomes.
The company has more than 20 umbrella patents related to three nanotechnology platforms with applications in oncology, bioavailability, and central nervous system disorders.
Its lead nanotherapeutic candidate, NBTXR3, is a novel oncology product that comprises functionalised hafnium oxide nanoparticles.
It is administered through a one-time intratumoral injection and activated by radiotherapy.
Nanobiotix designed the physical mechanism of action (MoA) of NBTXR3 to induce significant tumour cell death, along with triggering an immune response and long-term anti-cancer memory.
The company said that building on its physical MoA, NBTXR3 could be scalable across any solid tumour that can be treated with radiotherapy and across any therapeutic combination.
It is currently evaluating NBTXR3 in treating locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.
Nanobiotix unveiled favourable safety data and early signs of efficacy from its Phase 1 dose escalation and dose expansion study and launched a Phase 3 registrational study in 2021.
In February 2020, the US Food and Drug Administration (FDA) granted regulatory Fast Track designation for the investigation of NBTXR3, for the treatment of locally advanced HNSCC.
In September last year, Nanobiotix and LianBio randomised the first patient in Asia, in the Phase 3 NANORAY-312 trial evaluating NBTXR3 for the treatment of head and neck cancer.